The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
As per Thompi reamarks "Did you get under No.2 on the slide that there is a big pharma contract in progress? And also something about a spin-out under No.5?"
This is the last slide in English courtesy of twitter comments : -
"The presentation is in Korean. But the Google Lens translate of the final slide is interesting, including big pharma contract in progress and a spin out?
https://twitter.com/sandyradders/status/1788549727245447480/photo/1
I for one appreciate AS efforts on shareholfers behalf ,personally feel sad that he has left the company without completing has life long ambition.
Wish him the very best .
https://www.linkedin.com/in/alastair-smith-1b4b9111/recent-activity/all/
--------------------------
"Linkedin
Life Sciences ExecutiveLife Sciences Executive
Self-employedSelf-employed
Apr 2024 - Present · 2 mos
------------------
"Scientist by training and founder of Avacta Group plc, an AIM listed life sciences company.
Extensive experience of building early stage businesses within Avacta Group during nearly 20 years as a public company CEO. Excellent communicator and presenter of growth company investment opportunities. An effective team builder and business leader capable of delivering growth, and change when necessary, whilst maintaining a strong and positive culture within a business.
Significant management, strategic planning and transactional experience having led the public and private M&A activities of the Group since the IPO on AIM which was completed via a reverse merger.
Well known in the UK public markets, a respected and trusted executive with many years experience of investor relations in the UK, Europe and US. Successfully delivered multiple follow-on fund raisings for the Group totalling over £200m.
A scientist by training with a degree and PhD in Physics from Manchester University. Following a period of working in the US, returned in 1995 to take up an academic position at Leeds University. Became Professor of Molecular Biophysics at the age of 38, and over a ten years period, through close collaboration with life scientists, built one of the leading biophysics research groups in Europe before leaving an academic career in 2007 to focus full time on delivering value to Avacta shareholders.
Passionate about building successful life science businesses based on world-class science and great teams."
FYI - 08 May 2024
Vacancies List
Therapeutics
Medicinal Chemist
Scientist/Senior Scientist (Immunology)
Diagnostics
No current vacancies
---------------------------------
https://avacta.com/careers/scientist-senior-scientist-immunology/
https://avacta.com/careers/medicinal-chemist/
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Favacta.com%2Fwp-content%2Fuploads%2F2024%2F05%2FScientist-Snr-Immunology-April-2024-CAREERS-PAGE.docx&wdOrigin=BROWSELINK
https://avacta.com/wp-content/uploads/2024/05/Avacta-Medicinal-Chemist-May-2024-FINAL28.pdf
"Avacta Diagnostics expected to be overall EBITDA positive in second half of 2024 and cash generative 2025"
Anyway good or bad decision , it happened ,still on Avacta Balance sheet , so worthwhile making it work .
Perhaps Avacta might sell Coris & LD as seperate entities ?
@ Bella6532 : AMR Global issue not just the UK : Avacta well placed with Coris /LD :
"Anti-Microbial Resistance concern pushed Coris BioConcept to develop a range of assays (RESIST) for rapid detection of antibiotic resistance mechanisms. Aside of this range, another innovative approach for 3GC detection was recently launched with a front line test: BL-RED.
This R&D expertise is ideally suited for “on demand” production of innovative solutions in a rapidly changing world that calls for cutting edge biotechnology to take us forward into a healthy future.
All Coris BioConcept’s products fulfil the CE marking requirements with an ISO 13485 certification and they are used in over 60 countries all over the world.
Coris BioConcept is now part of Avacta Group."
----------------
"Coris BioConcept is a leading expert in the field of rapid diagnostics kits. Based in Belgium and established in 1996, the company develops, produces and markets diagnostic kits, mainly for the detection of human infectious pathogens (bacteria, virus and parasites), and for the detection of antibiotic resistance markers.
These rapid tests are based on the immunochromatographic (also known as lateral flow), the isothermal LAMP and the electrochemical technologies and are extensively used in microbiology laboratories worldwide.
Coris BioConcept is currently involved in multiple collaborative international projects (including Belgian and/or European grants) for the development of new rapid diagnostic assays, with focus on antimicrobial resistance and neglected tropical and emerging diseases.
This R&D expertise is ideally suited for the “on-demand” development or production of innovative solutions in a rapidly changing world that calls for cutting edge biotechnology to take us forward into a healthy future.
All Coris BioConcept’s products fulfill the CE marking requirements and the company is also certified ISO 13485.
--------------
Good timing
"Launch Diagnostics LimitedLaunch Diagnostics Limited
1,659 followers1,659 followers
1h • Edited • 1 hour ago
On the 4th April 2024 the Medicines and Healthcare products Regulatory Agency (MHRA) approved the combined antibiotic cefepime/enmetazobactam (brand name Exblifep) to treat adult patients with complicated infections of the urinary tract and certain types of pneumonia.
Enmetazobactam blocks the action of beta-lactamases, allowing cefepime to act against bacteria that would otherwise be resistant.
We are pleased to announce the addition of cefepime-enmetazobactam to the Liofilchem MTS (MIC Test Strip) range.
Launch Diagnostics is the exclusive distributor of Liofilchem's portfolio in the UK.
For all your AMR testing solutions, head over to our website: www.launchdiagnostics.com, or contact enquiries@launchdiagnostics.com
#microbiology #antimicrobialstewardship #antimicrobialresistance
#AMR #NHS #antibiotics #antimicrobials #patientcare"
Https://www.gov.uk/government/news/new-five-year-plan-to-combat-antimicrobial-resistance
https://www.grandviewresearch.com/industry-analysis/antibiotic-resistance-market
--------------------------
antimicrobial-resistance is a global problem -Opportunity for Coris/LD as they offer AMR detection products -
---- "The Group continues its focus on consolidating the Diagnostics Division post the Launch and Coris acquisitions. After the period end Avacta announced that it is exploring strategic options for the division in a manner which maximises shareholder value "
Anyway David Wilson Avacta Chief Commercial Officer | Driving Global IVD likes this
-----------------------
Department of Health and Social CareDepartment of Health and Social Care
262,695 followers262,695 followers
1h • 1 hour ago
Follow
Today we have launched a new plan to tackle antimicrobial resistance (AMR). This national action plan commits the UK to:
🔵 reduce use of antimicrobials
🔵 strengthen surveillance of drug resistant infections before they emerge
🔵 incentivise industry to develop the next generation of treatments
See our plan on Confronting Antimicrobial Resistance: https://lnkd.in/e9Xj6NxM
hashtag#AMR hashtag#AntimicrobialResistance
UK Research and Innovation, Department for Science, Innovation and Technology, UK Health Security Agency, Department for Environment, Food and Rural Affairs, Cabinet Office"
Might have a chance of winning : Avacta technology in action the science works .
-----------------
POC proven "pre|CISIONTM Concentrating highly potent warheads in the tumour microenvironment"
Courtesy of twitter :
https://twitter.com/BMHLTD/status/1787827592432681088
"*Note bottom of the slide*
An approx. 2-log reduction btwn. warhead conc. in the tumour(T) vs plasma(P).
In other words, 99% warhead release in the T, with only 1% in the P.
Explains > Tx index; + < SAE’s
If that isn’t pre | CISION oncology encapsulated, then what is?
1:51 PM · May 7, 2024
·
37
Views"
Https://www.mediscience-event.co.uk/nominations-overview/
"Best Technology Award
Shortlist
4basebio AG
Avacta Group plc
BiVictriX Therapeutics plc
Creo Medical Group plc
CRISPR Therapeutics
MaxCyte, Inc."
FYI :
"Congratulations to White City Innovation District's Avacta on its shortlisting in the European Mediscience Awards 2024 in the Best Technology category! 🎉
Now in its 22nd year, the European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe, showcasing outstanding achievement and success across these transformative sectors.
The European Mediscience Awards 2024 will take place on Thursday 13 June at the Hotel InterContinental, London, W1.
Discover more: https://lnkd.in/gaWTxaji
hashtag#WCID hashtag#WestTechCorridor hashtag#lifesciences hashtag#biotech"
Hi Thompi I had the same issue , this link helps how to do it . Yes think they will looking to licence out to numerous partners .Think stem cells technology very exciting looks like using affimers is the easy bit .
https://www.bing.com/videos/riverview/relatedvideo?q=you+tube+change+subtitles+to+english+video&mid=88F3E78863012EDF5FFB88F3E78863012EDF5FFB&FORM=VIRE
Actually says "resigned " anyway life goes on .
https://find-and-update.company-information.service.gov.uk/officers/mQJu_e3MPtLK1WR9Er1qwEh8SmY/appointments
https://find-and-update.company-information.service.gov.uk/company/04748597/filing-history
Just discovered you can get the subtitles in english easier to follow slide content if you put the speaker on mute .
Making progress on three products albeit AFX-001 timetable slipped about 12 months from previous presentation .
Lot more pre-clinical content & details on implementation strategy & objectives etc .
https://www.youtube.com/watch?v=hP0FBp1rESY
----------------------------
Previous video in english
https://www.bing.com/videos/riverview/relatedvideo?q=AffyXell+Therapeutics+KOREA+LOCAL+NEWS+ON+STEM+CELLS&mid=2CE92E1A797A979CE5DB2CE92E1A797A979CE5DB&FORM=VIRE
FYI Needs translation sorry to say looking at timetable ( 40mins ) phase one seems to be 2026 albeit IND filing 2025. ,
https://www.youtube.com/watch?v=hP0FBp1rESY
Anyway Avacta all about pre|CISIONTM now for next 12 months should be very exciting in own right .
Well might as well sack the complete board .
"The Chief Executive has direct charge of the Group on a day-to-day basis and is accountable to the Board for the financial and operational performance of the Group."
"The Board believes that given its balance sheet at the end of 2023 and following the fundraise at the beginning of 2024, it has the right strategy in place to be able to deliver significant value inflection points driven primarily by its well-funded therapeutic programmes, and also from growing its Diagnostic Division into an attractive profitable business the short term will together drive significant future shareholder value. "
With regard to CFO he is also the company secretary -so if replaced might need to hire two people .
- To my knowledge CFO has always met company fiscal responsibilities presenting accounts on time . While the accounts might not make good reading for some here hardly the CFO fault as he just presents the numbers & obtains auditor sign off . Whether the CFO was leading instrumental/responsible for the last fund raise is pure conjecture .
Dr Smith has taken the hit .
--------------------------------------
Anyway CC appointment details updated today https://avacta.com/investors/corporate-governance/
---------------------------------------
"The Chief Executive Officer, Dr Christina Coughlin, was appointed to the Board March 2022. Christina has an extensive background in the pharmaceutical and biotechnology fields, with a broad background of drug development from pre-IND to filing experience in global companies. Christina’s time commitment is full time."
-------------
Not new :
"Tony Gardiner was appointed as an Executive Director in January 2016 and fulfils the role of Chief Financial Officer for the Group. Tony has over 25 years’ experience in senior financial and operational roles across small and large organisations and has previously served as CFO in an AIM-listed business. In addition to this role, Tony is also Company Secretary and provides advice and guidance to the Board and Non-executive Directors. The Board acknowledges that best corporate governance practice would not combine the role of an Executive Director and Company Secretary; however, given the relative size of the Group at this stage, the Board is comfortable with Tony performing both roles but will review the position as the Group grows. Tony’s time commitment is full time."
Sorry this one :
https://twitter.com/YorkshirPuddin/status/1786293165613359306